Publications by authors named "G E Grubbs"
Safety and immunogenicity of a delayed booster dose of the rVSVΔG-ZEBOV-GP vaccine for prevention of Ebola virus disease: a multicentre, open-label, phase 2 randomised controlled trial.
Lancet Microbe
November 2024
Article Synopsis
- rVSVΔG-ZEBOV-GP is a vaccine that helps protect people from the Ebola virus and is the first one to be officially approved for this purpose.
- This study wanted to see how well a booster shot given 18 months after the first vaccine dose helped keep the immune response strong for a longer time.
- Healthy adults who might be at risk of exposure to Ebola participated in the trial, and the results measured their antibody levels 36 months after the first vaccination to compare those who got the booster with those who did not.
Limited knowledge exists on the quality of polyclonal antibody responses generated following Marburg virus (MARV) infection and its evolution in survivors. In this study, we evaluate MARV proteome-wide antibody repertoire longitudinally in convalescent phase approximately every six months for five years following MARV infection in ten human survivors. Differential kinetics were observed for IgM vs IgG vs IgA epitope diversity, antibody binding, antibody affinity maturation and Fc-receptor interaction to MARV proteins.
View Article and Find Full Text PDFThere is minimal knowledge regarding the durability of neutralization capacity and level of binding antibody generated against the highly transmissible circulating Omicron subvariants following SARS-CoV-2 infection in children with acute COVID-19 and those diagnosed with multisystem inflammatory syndrome in children (MIS-C) in the absence of vaccination. In this study, SARS-CoV-2 neutralization titers against the ancestral strain (WA1) and Omicron sublineages were evaluated in unvaccinated children admitted for COVID-19 ( = 32) and MIS-C ( = 32) at the time of hospitalization (baseline) and at six to eight weeks post-discharge (follow-up) between 1 April 2020, and 1 September 2022. In addition, antibody binding to the spike receptor binding domain (RBD) from WA1, BA.
View Article and Find Full Text PDFCyclopropylchloromethyldifluorosilane, c-C3H5SiF2CH2Cl, has been synthesized, and its rotational spectrum has been recorded by chirped-pulse Fourier transform microwave spectroscopy. The spectral analysis of several isotopologues indicates the presence of two distinct conformations in the free-jet expansion, which are interconvertible through a rotation of the chloromethyl group. A partial substitution structure is presented for the lower energy conformation and is compared to the equilibrium structure obtained from quantum chemical calculations.
View Article and Find Full Text PDFArticle Synopsis
- Two key monoclonal antibodies currently licensed for pre-treatment against RSV in infants are Palivizumab and Nirsevimab, targeting the viral fusion protein.
- This study creates new monoclonal antibodies from mice that target RSV G proteins, identifying six unique antigenic classes (G0-G5), though none effectively neutralize the virus in vitro.
- Despite not neutralizing the virus directly, these anti-G monoclonal antibodies significantly improve lung health and lower viral levels in mice after RSV infection, suggesting potential for new therapeutic options against RSV.